1. Home
  2. EOLS vs GBLI Comparison

EOLS vs GBLI Comparison

Compare EOLS & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • GBLI
  • Stock Information
  • Founded
  • EOLS 2012
  • GBLI 2016
  • Country
  • EOLS United States
  • GBLI United States
  • Employees
  • EOLS N/A
  • GBLI N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • GBLI Property-Casualty Insurers
  • Sector
  • EOLS Health Care
  • GBLI Finance
  • Exchange
  • EOLS Nasdaq
  • GBLI Nasdaq
  • Market Cap
  • EOLS 417.9M
  • GBLI 428.9M
  • IPO Year
  • EOLS 2018
  • GBLI 2003
  • Fundamental
  • Price
  • EOLS $6.96
  • GBLI $28.92
  • Analyst Decision
  • EOLS Strong Buy
  • GBLI
  • Analyst Count
  • EOLS 4
  • GBLI 0
  • Target Price
  • EOLS $21.25
  • GBLI N/A
  • AVG Volume (30 Days)
  • EOLS 1.4M
  • GBLI 2.5K
  • Earning Date
  • EOLS 11-05-2025
  • GBLI 10-30-2025
  • Dividend Yield
  • EOLS N/A
  • GBLI 4.84%
  • EPS Growth
  • EOLS N/A
  • GBLI N/A
  • EPS
  • EOLS N/A
  • GBLI 1.94
  • Revenue
  • EOLS $285,823,000.00
  • GBLI $441,717,000.00
  • Revenue This Year
  • EOLS $13.39
  • GBLI $5.48
  • Revenue Next Year
  • EOLS $26.85
  • GBLI $7.91
  • P/E Ratio
  • EOLS N/A
  • GBLI $14.95
  • Revenue Growth
  • EOLS 15.10
  • GBLI N/A
  • 52 Week Low
  • EOLS $5.71
  • GBLI $26.94
  • 52 Week High
  • EOLS $17.44
  • GBLI $37.00
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 55.80
  • GBLI 45.77
  • Support Level
  • EOLS $6.08
  • GBLI $29.00
  • Resistance Level
  • EOLS $7.76
  • GBLI $29.50
  • Average True Range (ATR)
  • EOLS 0.40
  • GBLI 0.20
  • MACD
  • EOLS 0.04
  • GBLI 0.02
  • Stochastic Oscillator
  • EOLS 54.17
  • GBLI 38.95

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

Share on Social Networks: